Gemopatrilat

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 108.16.195.87 (talk) at 17:25, 28 October 2017 (failed drug candidate). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Gemopatrilat
Clinical data
Other namesBMS-189921
ATC code
  • None
Identifiers
  • (6S)-Hexahydro-6-[(αS)-α-mercaptohydrocinnamido]-2,2-dimethyl-7-oxo-1H-azepine-1-acetic acid
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC19H26N2O4S
Molar mass378.49 g·mol−1
3D model (JSmol)
  • CC1(CCC[C@@H](C(=O)N1CC(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)S)C
  • InChI=1S/C19H26N2O4S/c1-19(2)10-6-9-14(18(25)21(19)12-16(22)23)20-17(24)15(26)11-13-7-4-3-5-8-13/h3-5,7-8,14-15,26H,6,9-12H2,1-2H3,(H,20,24)(H,22,23)/t14-,15-/m0/s1
  • Key:YRSVDSQRGBYVIY-GJZGRUSLSA-N

Gemopatrilat (INN)[1] is an experimental drug that was never marketed.[2] It acts as a vasopeptidase inhibitor.[3][4] It inhibits both angiotensin-converting enzyme (ACE) and neutral endopeptidase (neprilysin).[5]

References

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 46" (PDF). World Health Organization. p. 200. Retrieved 2 March 2017.
  2. ^ "Gemopatrilat". AdisInsight. Highest Development Phases: Discontinued
  3. ^ Laverman, GD; Van Goor, H; Henning, RH; De Jong, PE; De Zeeuw, D; Navis, G (January 2003). "Renoprotective Effects of VPI Versus ACEI in Normotensive Nephrotic Rats on Different Sodium Intakes". Kidney International. 63 (1): 64–71. doi:10.1046/j.1523-1755.2003.00708.x. PMID 12472769. Retrieved 2 March 2017.
  4. ^ Wait, JC; Vaccharajani, N; Mitroka, J; Jemal, M; Khan, S; Bonacorsi, SJ; Rinehart, JK; Iyer, RA (June 2006). "Metabolism of [14C]Gemopatrilat After Oral Administration to Rats, Dogs, and Humans" (PDF). Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34 (6): 961–70. doi:10.1124/dmd.105.007500. PMID 16540589. Retrieved 2 March 2017.
  5. ^ Hubner, RA; Kubota, E; Casley, DJ; Johnston, CI; Burrell, LM (May 2001). "In-vitro and in-vivo Inhibition of Rat Neutral Endopeptidase and Angiotensin Converting Enzyme with the Vasopeptidase Inhibitor Gemopatrilat". Journal of Hypertension. 19 (5): 941–6. PMID 11393678. {{cite journal}}: |access-date= requires |url= (help)
Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Gemopatrilat&oldid=807545468"